The FDA on May 22, 2020 approved ALUNBRIGĀ® for adult patients with Anaplastic Lymphoma Kinase (ALK)-positive metastatic Non-Small Cell Lung Cancer (NSCLC), as detected by an FDA-approved test. ALUNBRIGĀ® is a product of ARIAD Pharmaceuticals Inc.
Other Pages – Bottom Ad
Advertisement
Subscribe
